Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eribulin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sorafenib + Eribulin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Sorafenib (Nexavar, BAY43-9006) | DRUG | Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3). If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort. |
| Eribulin | DRUG | Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle. |
Inclusion Criteria: * Subjects with advanced, metastatic or refractory solid malignancy who are not candidates for standard therapy. For subject with metastatic breast cancer, prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. * Eastern Co...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Eribulin is an investigational small molecule oncology drug being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently in Phase 1 clinical development, meaning it is still being evaluated for safety and tolerability in humans and has not yet been approved for any medical use.
Eribulin is being developed by Bayer AG, a multinational pharmaceutical company headquartered in Germany. Bayer's stock is traded on the OTC market under the ticker symbol BAYRY. The company is conducting clinical research to evaluate the safety and potential anti-tumor activity of this investigational drug in patients with neoplasms.
Eribulin is currently in Phase 1 clinical development. This early-stage trial is designed to assess the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of the drug when used in combination with another agent. The Phase 1 study has been completed, and Eribulin remains an investigational drug that has not received regulatory approval.
Eribulin has been studied in one completed Phase 1 clinical trial registered as NCT01585870. This trial, titled 'Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination,' enrolled 40 adult participants with neoplasms at sites in France and Germany. The study was uncontrolled, meaning there was no comparator arm.
Eribulin is a small molecule that works by targeting and inhibiting microtubule dynamics. It binds to tubulin, a protein that is essential for cell division, and prevents the formation of functional mitotic spindles. This disrupts the process of mitosis, leading to cell cycle arrest and ultimately cell death, particularly in rapidly dividing cancer cells.